Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-15 · accession 0002001011-24-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-16 | 2024-02-15 | LGND | Davis Todd C | CEO, Dir | F - Tax | $74.65 | -1,381 | 71.7K | -2% | -$103.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | F | D | 1,381 | $74.65 | 71,709 | D | — | — | (F1) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |